Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.
Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.
复制标题
DOI：
10.1371/journal.pone.0014074
复制
发表时间：
2010-12-02
期刊：
影响因子：
3.7
通讯作者：
Mendelson JE
中科院分区：
文献类型：
--
作者：
Baggott MJ;Siegrist JD;Galloway GP;Robertson LC;Coyle JR;Mendelson JE
药物诱发视力的机制知之甚少。几十年来，很少有人在人类身上研究过多巴胺能致幻剂，尽管这些药物被广泛使用，而且它们的机制与精神和神经系统疾病中发生的幻觉可能相关。我们在一项双盲安慰剂对照研究中，通过测量致幻5-羟色胺5-HT 2AR受体激动剂和单胺抑制剂3，4-亚甲二氧基苯丙胺（MDA）的视觉和知觉效应，研究了致幻剂诱导的视觉的机制。我们发现，MDA增加了自我报告的神秘型经验和其他类似致幻剂的影响，包括报告的视觉改变的措施。MDA产生了显着的增加，闭眼视力（CEVs），具有相当大的个体差异。MDA后CEV的大小与轮廓整合和物体识别措施的较低性能相关。药物引起的视觉可能在感觉或知觉处理较差的人中具有更大的强度，这表明与其他幻觉综合征的共同机制。MDA是研究神秘体验和视觉感知的潜在工具。Clinicaltrials.gov NCT00823407
The mechanisms of drug-induced visions are poorly understood. Very few serotonergic hallucinogens have been studied in humans in decades, despite widespread use of these drugs and potential relevance of their mechanisms to hallucinations occurring in psychiatric and neurological disorders. We investigated the mechanisms of hallucinogen-induced visions by measuring the visual and perceptual effects of the hallucinogenic serotonin 5-HT2AR receptor agonist and monoamine releaser, 3,4-methylenedioxyamphetamine (MDA), in a double-blind placebo-controlled study. We found that MDA increased self-report measures of mystical-type experience and other hallucinogen-like effects, including reported visual alterations. MDA produced a significant increase in closed-eye visions (CEVs), with considerable individual variation. Magnitude of CEVs after MDA was associated with lower performance on measures of contour integration and object recognition. Drug-induced visions may have greater intensity in people with poor sensory or perceptual processing, suggesting common mechanisms with other hallucinatory syndromes. MDA is a potential tool to investigate mystical experiences and visual perception. Clinicaltrials.gov NCT00823407
登录
查看更多内容
影响因子：
2.6
作者：
Barnes, J;Boubert, L;David, AS
通讯作者：
David, AS
影响因子：
3.6
作者：
Baker, LE;Taylor, MM
通讯作者：
Taylor, MM
影响因子：
9.9
作者：
Biousse, V;Skibell, BC;Newman, NJ
通讯作者：
Newman, NJ
影响因子：
1.7
作者：
Carter, OL;Pettigrew, JD;Vollenweider, FX
通讯作者：
Vollenweider, FX
DOI：
10.1001/archneurpsyc.1956.02330240026003
发表时间：
1956-01-01
影响因子：
--
作者：
BERCEL, NA;TRAVIS, LE;DREIKURS, E
通讯作者：
DREIKURS, E